HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
Study details:
This is a first-in-human, Phase 0/1, open-label study of 177Lu-RAD202 consisting of a Screening Period, a Treatment Period with 177Lu-RAD202 and a Safety and Long-Term Follow-Up Period to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours. Screening Period: Screening period of up to 4 weeks Phase I (Treatment Period): 177Lu-RAD202 dose escalation. * Treatment Period with each cycle lasting 6 weeks.
Extension of the planned dose intervals are possible following discussion and agreement between the Sponsor and Investigator. * Participants may be treated with multiple cycles as long as they appear to derive clinical benefit as determined by the Investigator and provided adequate clinical safety and organ dosimetry data. * DLT observation period for 177Lu-RAD202 is 6 weeks following first injection of 177Lu-RAD202.
* Should an alternative treatment schedule be explored, the DLT observation period for 177Lu-RAD202 at that dose level will be the proposed cycle duration. Safety Follow-Up Period:. * An End of Treatment Visit performed within 7 days of the last dose of 177Lu-RAD202.
* A Safety Follow-up Visit performed every 12 ± 2 weeks from the End of Treatment Visit.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
- Aged 18 years and older.
- Written, voluntary, informed consent of the participants must be obtained in compliance with institutional, regional, and federal guidelines.
- Participants with histologically or cytologically confirmed, HER2 positive advanced solid tumours that are relapsed/refractory, locally advanced not amenable to curative-intent therapy, or metastatic, with documented disease progression during or after their most recent line of anti-cancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.
- Must have at least 1 measurable target lesion according to RECIST version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
- Participants must have a life expectancy of ≥4 months in the opinion of the Investigator.
- Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
- WOCBP must agree to use a highly effective method of contraception during the study and for 60 days after the last dose of 177Lu-RAD202.
- Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202.
- Participants with previously treated brain metastases are eligible to participate if they are neurologically and radiologically stable, do not require steroids to treat associated neurological symptoms, and have no history of leptomeningeal disease or spinal.
- For Phase 1 (Treatment Period): Participants must have positive lesion(s) by 177Lu-RAD202im SPECT/CT per central review.
Exclusion criteria
- Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
- Participants who have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time-point imaging procedures, etc.
- Residual toxicity Grade ≥ 2 from previously administered therapy (except for alopecia).
- Inadequate organ functions as reflected in laboratory parameters: Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min; Platelet count of < 100 x 109/L; Absolute neutrophil count (ANC) < 1.5 x 109/L; Haemoglobin < 9 g/dL; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN, or > 5 x ULN for patients with known liver metastases; Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN; For participants not taking warfarin or other anticoagulants: international normalised ratio (INR) ≤1.5 or prothrombin time (PT) ≤1.5 x ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≤1.5 x ULN. Participants taking warfarin must be on a stable dose that results in a stable INR <3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
- Significant cardiovascular disease including: Unstable angina and/or myocardial infarction within 6 months prior to screening; New York Heart Association Class II or greater congestive heart failure; Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block); QTcF > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome; Uncontrolled hypertension; Known LVEF < 50%.
- History of uncontrolled allergic reactions and/or have hypersensitivity to anti-HER2 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity.
- Pregnant or lactating women.
- Participants who are receiving any other investigational agents.
- Major surgery within 4 weeks prior to first dose of 177Lu-RAD202tr. Exceptions may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
- Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD202tr.
- Has had or is scheduled to have major surgery ≤28 days prior to the first dose of 177Lu-RAD202tr. Elective surgical procedures not considered to put participants at higher risk of AEs may be allowed on a case-by-case basis in discussion with the Sponsor.
- Positive status for human immunodeficiency virus (HIV).
- Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.
- Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.
- Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.
Eligibility
Age eligible for study : NA
Healthy volunteers accepted : No
Gender eligible for study: ALL
Things to know
Study dates
Study start:
Primary completion:
Study completion finish:
Study type
TREATMENT
Phase
- EARLY_PHASE1
Study ID
NCT06824155
Intervention or treatment
DRUG: 177Lu-RAD202
Conditions
- HER2 Gene Mutation
- Advanced Solid Tumors
You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.
Research sites nearby
Closest Location:
Nepean Hospital
Select from list below to view details:
Nepean Hospital
Kingswood, New South Wales, Australia
GenesisCare Murdoch
Murdoch, Western Australia, Australia
Loading map...
Who is running the clinical trial?
Radiopharm Theranostics, Ltd
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: 177Lu-RAD202
| Drug: 177Lu-RAD202 |
What is the study measuring?
Primary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Time Activity Curves (TACs) | Percent of the injected activity vs time for selected organs and tumors | 72 hours |
| Radiation dosimetry of Lu177-RAD202im | Absorbed radiation doses of 177Lu-RAD202im in critical organs (e.g., kidneys, bone marrow) | 72 hours |
| Safety and tolerability of a single dose of 177Lu-RAD202tr | The properties, incidence, nature and severity of AEs and SAEs per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | 6 weeks |
| Recommended dose(s) of 177Lu-RAD202tr for future exploration | Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD202tr injection cycle of treatment | 6 weeks |
| Pharmacokinetics of 177Lu-RAD202im | Half-life of 177Lu-RAD202im in blood | 72 hours |
| Biokinetics of 177Lu-RAD202im | Time-integrated activity coefficients of 177Lu-RAD202im in organs and tumor lesions | 72 hours |
Secondary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability of 177Lu-RAD202im | The properties, incidence, nature and severity of AEs and SAEs per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | 6 weeks |
| Recommended dose(s) of 177Lu-RAD202im for future exploration | Incidence of dose-limiting toxicities (DLTs) in the first 2 weeks following 177Lu-RAD202im injection | 2 weeks |
| Preliminary antitumor activity of 177Lu-RAD202tr | Objective response rates (ORR) as assessed by RECIST v1.1 | Up to 30 weeks |
| Radiation dosimetry of 177Lu-RAD202tr | Absorbed radiation doses of 177Lu-RAD202tr in critical organs (e.g., kidneys, bone marrow) | 72 hours |
References
Clinical Trials Gov: HEAT Trial (HER2 Antibody Therapy With Lutetium-177)Other trials to consider
Loading suggested trials...
